>
Powered by

Semma Therapeutics attracts funding

Cambridge, Massachusetts-based Semma Therapeutics, a developer of cell therapy for Type 1 diabetes, has raised an undisclosed amount of funding. The investor was JDRF T1D Fund, a venture philanthropy fund.

PRESS RELEASE

BOSTON, MA – March 22, 2017 – Semma Therapeutics, a biopharmaceutical company developing Stem Cell-derived Islet therapy for type 1 diabetes (T1D), today announced it has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devote

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox